As of 3:59pm ET
| +0.36 / +3.06%|
The 6 analysts offering 12-month price forecasts for Trinity Biotech PLC have a median target of 20.00, with a high estimate of 28.00 and a low estimate of 14.00. The median estimate represents a +65.15% increase from the last price of 12.11.
The current consensus among 7 polled investment analysts is to Buy stock in Trinity Biotech PLC. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.